Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 755 across all filing types
Latest filing 2019-04-18 Board/Management Inform…
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
Director Appointment
Board/Management Information Classification · 95% confidence The document is a company announcement dated 18 April 2019 regarding the appointment of John Duncan as an Independent Director to the Board of Pacific Edge Limited. It provides background information on the appointee and the company's business but does not contain financial data, regulatory filings, or report publications. The primary content is about a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 5121 characters, sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is MANG with high confidence.
2019-04-18 English
Request for Director Nominations
Board/Management Information Classification · 95% confidence The document is an announcement requesting director nominations for the upcoming Annual Meeting of Pacific Edge Limited. It specifies dates for nominations and references the Annual Meeting but does not contain any financial data, voting results, or detailed meeting materials. It is not a report or a voting result announcement but rather a notice related to board/management matters, specifically director nominations. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management nominations, confirming this classification.
2019-04-16 English
Cxbladder Adoption Roll-Out Advances in New Zealand
Regulatory Filings Classification · 95% confidence The document is a press release dated 18 March 2019 from Pacific Edge Limited announcing the roll-out and adoption of their Cxbladder diagnostic tests by a New Zealand public healthcare provider. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or operational analysis. The content is primarily a business update about product adoption and commercial agreements. The document length is 6155 characters, which is relatively short and consistent with a press release or announcement rather than a detailed report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal regulatory filing. It does not fit into categories like M&A, Capital Update, or Legal Proceedings. The best fitting category is Regulatory Filings (RNS), which is the fallback for general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-03-17 English
NZXR Share Price Enquiry into Pacific Edge Limited
Regulatory Filings Classification · 95% confidence The document is a letter from NZX Limited to the CEO of Pacific Edge Limited regarding a price enquiry under Listing Rule 10.1.1 about continuous disclosure of material information. It discusses a recent fall in the company's share price and requests confirmation of compliance with disclosure rules. The document is a regulatory communication related to compliance and disclosure obligations, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is under 5,000 characters and is essentially a regulatory inquiry letter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2019-02-14 English
SPH Notice – First NZ Capital Group Limited
Major Shareholding Notification Classification · 100% confidence The document is a disclosure of movement of 1% or more in substantial holding or change in nature of relevant interest under the Financial Markets Conduct Act 2013. It details changes in share ownership percentages and holdings by substantial product holders, including specific numbers of shares held and percentages. The document is a formal notification to the NZX Limited and Pacific Edge Limited about changes in substantial shareholdings. This matches the definition of a Major Shareholding Notification, which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other financial report type, nor is it an announcement of a report publication. It is a regulatory disclosure about shareholding changes.
2019-02-04 English
D&O Ongoing Disclosures – Multiple
Regulatory Filings
2019-02-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.